Radiation induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: A review of new avenues in its management

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Chen, Jing ^a   Dassarath, Meera ^a,b   Yin, Zhongyuan ^a   Liu, Hongli ^a   Yang, Kunyu ^a   Wu, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Queen Victoria Hospital   (Mauritius)

Author keywords

Bevacizumab; Nasopharyngeal cancer; Radiation therapy; Temporal lobe necrosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BEVACIZUMAB; CHOLINE; CREATININE; DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18; N ACETYLASPARTIC ACID; PENTOXIFYLLINE; PLACEBO; STEROID; TICLOPIDINE; VASCULOTROPIN; ANTICOAGULANT AGENT; MONOCLONAL ANTIBODY; OXYGEN; VITAMIN;

BRAIN BLOOD FLOW; BRAIN NECROSIS; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG MEGADOSE; FOLLOW UP; HUMAN; HYPERBARIC OXYGEN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; INTENSITY MODULATED RADIATION THERAPY; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; OXYGEN TOXICITY; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RADIATION NECROSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; TEMPORAL LOBE NECROSIS; TREATMENT OUTCOME; CHEMISTRY; METABOLISM; METHODOLOGY; NASOPHARYNX TUMOR; NECROSIS; PATHOLOGY; RADIATION EXPOSURE; RADIATION INJURY; RADIOTHERAPY; TEMPORAL LOBE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NASOPHARYNGEAL NEOPLASMS; NECROSIS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIATION INJURIES; RADIOTHERAPY; STEROIDS; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; VITAMINS;

EID: 80053355735     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-128     Document Type: Review

References (74)

1. Nielsen N, Mikkelsen F, Hansen J. Nasopharyngeal cancer in Greenland. Acta Pathologica Microbiologica Scandinavica Section A Pathology 1977, 85:850-858.
2. Perez CA, Brady LW. Principles and Practice of Radiation Oncology 2008, 5.
3. Yi JL, Gao L, Huang XD, Li SY, Luo JW, Cai WM, Xiao JP, Xu GZ. Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution. Int J Radiat Oncol Biol Phys 2006, 65:161-168. 10.1016/j.ijrobp.2005.12.003, 16542792.
4. Lee AW, Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, Law SC, Ng SH, O SK, Tung SY, et al. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1998, 40:35-42. 10.1016/S0360-3016(97)00580-4, 9422555.
5. Leung SF, Kreel L, Tsao SY. Asymptomatic temporal lobe injury after radiotherapy for nasopharyngeal carcinoma: incidence and determinants. Br J Radiol 1992, 65:710-714. 10.1259/0007-1285-65-776-710, 1393399.
6. Rubenstein LJ. Radiation changes in intracranial neoplasms and the adjacent brain. Book Radiation changes in intracranial neoplasms and the adjacent brain 1970, 349-360. (Editor ed.^eds.). pp. 349-360. City;.
7. Giglio P, Gilbert M. Cerebral radiation necrosis. The Neurologist 2003, 9:180. 10.1097/01.nrl.0000080951.78533.c4, 12864928.
8. Cheng KM, Chan CM, Fu YT, Ho LC, Cheung FC, Law CK. Acute hemorrhage in late radiation necrosis of the temporal lobe: report of five cases and review of the literature. J Neurooncol 2001, 51:143-150. 10.1023/A:1010631112015, 11386411.
9. Lee AW, Ng SH, Ho JH, Tse VK, Poon YF, Tse CC, Au GK, O SK, Lau WH, Foo WW. Clinical diagnosis of late temporal lobe necrosis following radiation therapy for nasopharyngeal carcinoma. cancer 1988, 61:1535-1542. 10.1002/1097-0142(19880415)61:8<1535::AID-CNCR2820610809>3.0.CO;2-E, 3349419.
10. Glass JP, Hwang TL, Leavens ME, Libshitz HI. Cerebral radiation necrosis following treatment of extracranial malignancies. Cancer 1984, 54:1966-1972. 10.1002/1097-0142(19841101)54:9<1966::AID-CNCR2820540930>3.0.CO;2-4, 6478431.
11. Ho JHC. Treatment of cancer 1982, London: Chapman & Hall.
12. Dassarath M, Yin Z, Chen J, Liu H, Yang K, Wu G. Temporal lobe necrosis: a dwindling entity in a patient with nasopharyngeal cancer after radiation therapy. Head & Neck Oncology 2011, 3:1-6. 10.1186/1758-3284-3-1, 3169868, 21966646.
13. Lee AW, Cheng LO, Ng SH, Tse VK, O SK, Au GK, Poon YF. Magnetic resonance imaging in the clinical diagnosis of late temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. Clin Radiol 1990, 42:24-31. 10.1016/S0009-9260(05)81617-4, 2390834.
14. Van Tassel P, Bruner JM, Maor MH, Leeds NE, Gleason MJ, Yung WK, Levin VA. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. AJNR Am J Neuroradiol 1995, 16:715-726.
15. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000, 217:377-384.
16. Tsui EY, Chan JH, Leung TW, Yuen MK, Cheung YK, Luk SH, Tung SY. Radionecrosis of the temporal lobe: dynamic susceptibility contrast MRI. Neuroradiology 2000, 42:149-152. 10.1007/s002340050036, 10663496.
17. Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, Jung HW, Chang KH. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: Assessing the efficacy of (18)F-FDG PET, (11)C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010, 112:758-765. 10.1016/j.clineuro.2010.06.005, 20619531.
18. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002, 223:11-29. 10.1148/radiol.2231010594, 11930044.
19. Benveniste H, Hedlund L, Johnson G. Mechanism of detection of acute cerebral ischemia in rats by diffusion-weighted magnetic resonance microscopy. Stroke 1992, 23:746. 10.1161/01.STR.23.5.746, 1374575.
20. Ikezaki K, Takahashi M, Koga H, Kawai J, Kovacs Z, Inamura T, Fukui M. Apparent diffusion coefficient (ADC) and magnetization transfer contrast (MTC) mapping of experimental brain tumor. Acta neurochirurgica Supplement 1997, 70:170.
21. Tsui E, Chan J, Ramsey R, Leung T, Cheung Y, Luk S, Lai K, Wong K, Fong D, Yuen M. Late temporal lobe necrosis in patients with nasopharyngeal carcinoma: evaluation with combined multi-section diffusion weighted and perfusion weighted MR imaging. European journal of radiology 2001, 39:133-138. 10.1016/S0720-048X(01)00328-X, 11566238.
22. Le Bihan D, Turner R, Douek P, Patronas N. Diffusion MR imaging: clinical applications. American Journal of Roentgenology 1992, 159:591.
23. Heesters MA, Kamman RL, Mooyaart EL, Go KG. Localized proton spectroscopy of inoperable brain gliomas. Response to radiation therapy. J Neurooncol 1993, 17:27-35. 10.1007/BF01054271, 8120569.
24. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997, 87:516-524. 10.3171/jns.1997.87.4.0516, 9322842.
25. Chong VF, Rumpel H, Fan YF, Mukherji SK. Temporal lobe changes following radiation therapy: imaging and proton MR spectroscopic findings. Eur Radiol 2001, 11:317-324. 10.1007/s003300000548, 11218034.
26. Esteve F, Rubin C, Grand S, Kolodie H, Le Bas JF. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998, 40:279-286. 10.1016/S0360-3016(97)00714-1, 9457810.
27. Smith EA, Carlos RC, Junck LR, Tsien CI, Elias A, Sundgren PC. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009, 192:W45-52. 10.2214/AJR.07.3934, 19155380.
28. Di Chiro G, Fulham MJ. Virchow's shackles: can PET-FDG challenge tumor histology?. AJNR Am J Neuroradiol 1993, 14:524-527.
29. Davis WK, Boyko OB, Hoffman JM, Hanson MW, Schold SC, Burger PC, Friedman AH, Coleman RE. [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR Am J Neuroradiol 1993, 14:515-523.
30. Janus T, Kim E, Tilbury R, Bruner J, Yung W. Use of [18F] fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Annals of Neurology 1993, 33:540-548. 10.1002/ana.410330520, 8498831.
31. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 1998, 19:407-413.
32. Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WK, Moser RP, et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 1992, 12:269-279.
33. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994, 163:1459-1465.
34. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000, 41:1861-1867.
35. Xiangsong Z, Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol 2007, 82:305-311. 10.1007/s11060-006-9286-y, 17120157.
36. Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, Kim SW, Chung JH. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J 2010, 57:1045-1054. 10.1507/endocrj.K10E-258, 20978365.
37. Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 2008, 10:1-18. 10.1007/s11307-007-0115-2, 17957408.
38. Schwartz RB, Carvalho PA, Alexander E, Loeffler JS, Folkerth R, Holman BL. Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope SPECT with 201TI and 99mTc-HMPAO. AJNR Am J Neuroradiol 1991, 12:1187-1192.
39. Brismar T, Collins VP, Kesselberg M. Thallium-201 uptake relates to membrane potential and potassium permeability in human glioma cells. Brain Res 1989, 500:30-36. 10.1016/0006-8993(89)90296-5, 2605498.
40. Kaplan WD, Takvorian T, Morris JH, Rumbaugh CL, Connolly BT, Atkins HL. Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med 1987, 28:47-52.
41. Black KL, Hawkins RA, Kim KT, Becker DP, Lerner C, Marciano D. Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg 1989, 71:342-346. 10.3171/jns.1989.71.3.0342, 2549223.
42. Kim KT, Black KL, Marciano D, Mazziotta JC, Guze BH, Grafton S, Hawkins RA, Becker DP. Thallium-201 SPECT imaging of brain tumors: methods and results. J Nucl Med 1990, 31:965-969.
43. Yoshii Y, Satou M, Yamamoto T, Yamada Y, Hyodo A, Nose T, Ishikawa H, Hatakeyama R. The role of thallium-201 single photon emission tomography in the investigation and characterisation of brain tumours in man and their response to treatment. European Journal of Nuclear Medicine and Molecular Imaging 1993, 20:39-45.
44. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999, 59:5452-5455.
45. Hou X, Zhao C, Guo Y, Han F, Lu LX, Wu SX, Li S, Huang PY, Huang H, Zhang L. Different Clinical Significance of Pre- and Post-treatment Plasma Epstein-Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy. Clin Oncol (R Coll Radiol) 2011, 23:128-133.
46. Leung S, Chan A, Zee B, Ma B, Chan L, Johnson P, Dennis Lo Y. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early stage nasopharyngeal carcinoma of undifferentiated type. cancer 2003, 98:288-291. 10.1002/cncr.11496, 12872347.
47. Kam M, Chau R, Suen J, Choi P, Teo P. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation* 1. International Journal of Radiation Oncology* Biology* Physics 2003, 56:145-157.
48. Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol 2011, 98:23-27. 10.1016/j.radonc.2010.10.009, 21040992.
49. Wang W, Yang H, Hu W, Shan G, Ding W, Yu C, Wang B, Wang X, Xu Q. Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2010, 77:617-621. 10.1016/j.ijrobp.2009.08.036, 20138444.
50. Lee A, Kwong D, Leung S, Tung S, Sze W, Sham J, Teo P, Leung T, Wu P, Chappell R. Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time. International Journal of Radiation Oncology* Biology* Physics 2002, 53:75-85.
51. Yeh SA, Tang Y, Lui CC, Huang YJ, Huang EY. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005, 62:672-679. 10.1016/j.ijrobp.2004.11.002, 15936544.
52. Hara W, Loo BW, Goffinet DR, Chang SD, Adler JR, Pinto HA, Fee WE, Kaplan MJ, Fischbein NJ, Le QT. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008, 71:393-400. 10.1016/j.ijrobp.2007.10.027, 18164839.
53. Lee AW, Ng WT, Hung WM, Choi CW, Tung R, Ling YH, Cheng PT, Yau TK, Chang AT, Leung SK, et al. Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors. Int J Radiat Oncol Biol Phys 2009, 73:1121-1128. 10.1016/j.ijrobp.2008.05.023, 18723296.
54. Lam TC, Wong FC, Leung TW, Ng SH, Tung SY. Clinical Outcomes of 174 Nasopharyngeal Carcinoma Patients with Radiation-Induced Temporal Lobe Necrosis. Int J Radiat Oncol Biol Phys
55. Tada E, Matsumoto K, Kinoshita K, Furuta T, Ohmoto T. The protective effect of dexamethasone against radiation damage induced by interstitial irradiation in normal monkey brain. Neurosurgery 1997, 41:209-217. discussion 217-209., 10.1097/00006123-199707000-00033, 9218309.
56. Benoit A, Ducray F, Cartalat-Carel S, Psimaras D, Ricard D, Honnorat J. Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. J Neurol 2011, 258:328-329.
57. Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold SC. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994, 44:2020-2027.
58. Chan AS, Cheung MC, Law SC, Chan JH. Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. cancer 2004, 100:398-404. 10.1002/cncr.11885, 14716777.
59. Gabb G, Robin ED. Hyperbaric oxygen. A therapy in search of diseases. Chest 1987, 92:1074-1082. 10.1378/chest.92.6.1074, 3315479.
60. Chuba PJ, Aronin P, Bhambhani K, Eichenhorn M, Zamarano L, Cianci P, Muhlbauer M, Porter AT, Fontanesi J. Hyperbaric oxygen therapy for radiation-induced brain injury in children. cancer 1997, 80:2005-2012. 10.1002/(SICI)1097-0142(19971115)80:10<2005::AID-CNCR19>3.0.CO;2-0, 9366305.
61. Feldmeier JJ, Heimbach RD, Davolt DA, Brakora MJ, Sheffield PJ, Porter AT. Does hyperbaric oxygen have a cancer-causing or -promoting effect? A review of the pertinent literature. Undersea Hyperb Med 1994, 21:467-475.
62. Feldmeier J, Carl U, Hartmann K, Sminia P. Hyperbaric oxygen: does it promote growth or recurrence of malignancy?. Undersea Hyperb Med 2003, 30:1-18.
63. Lin HY, Ku CH, Liu DW, Chao HL, Lin CS, Jen YM. Hyperbaric oxygen therapy for late radiation-associated tissue necroses: is it safe in patients with locoregionally recurrent and then successfully salvaged head-and-neck cancers?. Int J Radiat Oncol Biol Phys 2009, 74:1077-1082. 10.1016/j.ijrobp.2008.08.076, 19327913.
64. Hsu YC, Wang LF, Lee KW, Ho KY, Huang CJ, Kuo WR. Cerebral radionecrosis in patients with nasopharyngeal carcinoma. Kaohsiung J Med Sci 2005, 21:452-459. 10.1016/S1607-551X(09)70150-0, 16302448.
65. Leung TW, Tung SY, Sze WK, Wong FC, Yuen KK, Lui CM, Lo SH, Ng TY, O SK. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns. Head Neck 2005, 27:555-565. 10.1002/hed.20189, 15880410.
66. Mou YG, Sai K, Wang ZN, Zhang XH, Lu YC, Wei DN, Yang QY, Chen ZP. Surgical management of radiation-induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: Report of 14 cases. Head Neck 2010,
67. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67:323-326. 10.1016/j.ijrobp.2006.10.010, 17236958.
68. Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009, 94:63-68. 10.1007/s11060-009-9801-z, 19189055.
69. Wong ET, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 2008, 26:5649-5650. 10.1200/JCO.2008.19.1866, 18981459.
70. Kim JH, Chung YG, Kim CY, Kim HK, Lee HK. Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci 2004, 19:879-886. 10.3346/jkms.2004.19.6.879, 2816293, 15608402.
71. Li YQ, Ballinger JR, Nordal RA, Su ZF, Wong CS. Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 2001, 61:3348-3354.
72. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys 2011, 79:1487-1495. 10.1016/j.ijrobp.2009.12.061, 20399573.
73. Furuse M, Kawabata S, Kuroiwa T, Miyatake SI. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 2011, 102:471-475. 10.1007/s11060-010-0333-3, 20694573.
74. Wang X, Ying H, Zhou Z, Hu C, Eisbruch A. Successful Treatment of Radiation-Induced Temporal Lobe Necrosis With Mouse Nerve Growth Factor. J Clin Oncol 2011, 29:e166-168. 10.1200/JCO.2010.31.7081, 21149661.